Gleason Score 9-10 vs. Gleason 8 Associated with Worse Outcomes

Share this content:

the Cancer Therapy Advisor take:

Men who have a localized prostate biopsy Gleason 9-10 with definitive local therapy face worse outcomes compared to those with biopsy Gleason 8 disease, according to a recent study published in The Journal of Urology.

Che-kai Tsao, MD, of the Division of Hematology and Medical Oncology at The Tisch Cancer Institute at Mount Sinai in New York observed a cohort of 847 patients with biopsy Gleason 8-10 disease who had received either radiation therapy (RT) or radical prostatectomy (RP) from January 2001 to December 2011.

They used multivariable Cox modeling to compare outcomes in Gleason score of 8 and 9-10 in terms of time to biochemical recurrence, time to metastases, and overall survival. At baseline, patients demonstrated similar characteristics between the two groups.

The researchers found that higher-grade disease was associated with an increased risk of developing metastatic disease, with an increased risk of death in Gleason 9-10, particularly among those treated with RP. Gleason 9-10 was also associated with higher PSA at diagnosis.

“Clinical trials incorporating newer approaches to Gleason 9-10 cancer are urgently needed,” the authors concluded.

Capsule and biopsy probes and Gleason volumes
Men who have a localized prostate biopsy Gleason 9-10 with definitive local therapy face worse outcomes.
In this study, authors want to examine the differences in outcome in patients with biopsy Gleason score 8 versus 9-10 who received definitive local therapy. Patients with localized biopsy Gleason 9-10 disease treated with definitive local therapy had worse outcomes compared to patients diagnosed with biopsy Gleason 8 disease.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs